Newsletter Tool

Today’s Big News

Aug 15, 2024

ArriVent licenses ADC from $100M biobuck deal with Aarvik

Turnstone narrows cell therapy focus to 'high unmet need' tumor indications

After clearing out heart disease drug, Arrowhead maps out obesity development plans

Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO

Denali reports new method to get antisense oligonucleotides across blood-brain barrier

Featured

ArriVent licenses ADC from $100M biobuck deal with Aarvik

By James Waldron

Two and half years after it signed a $100 million biobucks deal with Aarvik Therapeutics to work on an undisclosed “novel oncology drug,” ArriVent BioPharma has decided to license the candidate—and confirmed that it’s an antibody-drug conjugate.

Turnstone narrows cell therapy focus to 'high unmet need' tumor indications

By James Waldron

Turnstone Biologics is narrowing the focus of phase 1 trials of its lead tumor-infiltrating lymphocyte, with cutaneous melanoma and breast cancer no longer in the mix.

After clearing out heart disease drug, Arrowhead maps out obesity development plans

By Gabrielle Masson

After Arrowhead cleared out work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both slated to enter the clinic in early 2025.

Cancer-focused Actuate is latest biotech on Nasdaq after $22.4M IPO

By James Waldron

Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million.

Denali reports new method to get antisense oligonucleotides across blood-brain barrier

By Darren Incorvaia

Antisense oligonucleotides, which bind to RNA and prevent them from being translated into proteins, have gained popularity in recent years as a way to treat neurodegenerative diseases. However, getting these drugs into the brain has been challenging, requiring invasive infusion directly into the cerebrospinal fluid.

IRA negotiations slash Medicare prices for Big Pharma blockbusters by up to 79%

By Kevin Dunleavy,Fraiser Kansteiner

The White House has revealed significantly reduced prices for 10 prescription drugs affected by the first wave of Medicare negotiations mandated by the Inflation Reduction Act, the Biden administration initiative which includes several measures designed to lower the cost of healthcare in the U.S.

Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia

By Kevin Dunleavy

Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in competition to attract patients to their respective treatments for sickle cell disease.

Incyte, Syndax bag FDA approval for potential blockbuster Niktimvo in graft-versus-host disease

By Angus Liu

Incyte has expanded its graft-versus-host disease offerings beyond Jakafi. The new addition comes from Syndax Pharma-partnered axatilimab, which received FDA approval as a third-line therapy.

With FDA approval of Livdelzi, Gilead launches an inflammatory drug for the first time

By Kevin Dunleavy

The FDA has approved Gilead's primary biliary cholangitis treatment Livdelzi. The drug, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago, is the first inflammatory treatment launched by Gilead.

Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO

By Fraiser Kansteiner

Roughly one year since the commercial rollout of Tarsus Pharmaceuticals’ first marketed product Xdemvy, the company is touting the medicine’s debut as “one of the most successful eye care launches to date.”

Fierce podcasts

Don’t miss an episode

A closer look at Fierce Biotech's Fierce 15

In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report.

What the data says about the telehealth market

Fierce 15: Where are they now?

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.